Moomoo report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Why QTEX Stock dropped -8.20% Today — RQD Quant Desk Flash
QTREX Quantum Ltd. (QTEX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is QTEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.12 (-8.20% 1D, market cap $62.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QTEX ranks #570 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does QTEX compare to SKIN and LNSR in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, SKIN (SkinHealth Systems Inc. (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -26.9%, cap $67.5M) and LNSR (LENSAR Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $69.7M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for QTEX?
▼
Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue (-99.1% YoY), -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a QTEX Turnaround Squeeze
While QTEX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.10) and Max Pain ($1.18) forces dealer call-delta covering toward $4.04.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why QTEX Stock dropped -8.20% Today — RQD Quant Desk Flash
QTREX Quantum Ltd. (QTEX) dropped -8.20% to $1.12, trading at 24% of its 52-week range ($0.28 – $3.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 24% of its 52-week range ($0.28 – $3.85) with RSI-14 at 42 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.12 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 0.2% gross margin and $0 annual free cash flow.
Yahoo Finance report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Globes - Israel Business News report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Ness Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrast
QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, announced today that
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QTEX)
- ✓Walkthrough of QTEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
QTEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -99.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on QTEX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for QTEX. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTEX)
1. Head-to-Head Health Care Peer Comparison (QTEX vs. SKIN, LNSR, MBOT, DXR)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, QTREX Quantum Ltd. (QTEX) ranks #570 by composite RQD confidence (36/100, grade D-) and #711 by equity capitalization ($62.7M). Within this direct 5-issuer industry benchmark cohort, QTEX leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DXR currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QTEX at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QTEX
ACTIVE
QTREX Quantum Ltd. | D- | 36/100 | — | 0.7% | -35.0% | -8.20% | $62.7M | Benchmark Subject |
| SKIN SkinHealth Systems Inc. (Class A) | E | 32/100 | — | 65.3% | -26.9% | +4.43% | $67.5M | /skin-vs-qtex → |
| LNSR LENSAR Inc. | E | 18/100 | — | 39.4% | -35.0% | -2.91% | $69.7M | /lnsr-vs-qtex → |
| MBOT Microbot Medical Inc. | E | 29/100 | — | — | -15.8% | -4.59% | $69.9M | /mbot-vs-qtex → |
| DXR Daxor Corporation | D | 47/100 | — | — | — | -2.17% | $52.5M | /dxr-vs-qtex → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001837493 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), QTREX Quantum Ltd. (QTEX) reported GAAP revenue of $289.0K (-99.1% vs. FY2024 revenue of $31.5M , and -99.1% cumulative change since FY2023) , GAAP net income of -$13.2M, operating cash flow of -$9.9M, and free cash flow of -$10.0M (-4.5% YoY). On the balance sheet, QTEX closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $289.0K | -$13.2M | -$9.9M | -$10.0M | $5.3M | — |
| FY2024 (FY) | 2024-12-31 | $31.5M | -$11.1M | -$9.4M | -$9.5M | $8.1M | — |
| FY2023 (FY) | 2023-12-31 | $34.0M | -$11.3M | -$9.7M | -$9.7M | — | — |
3. QTEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs QTEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.12 (-8.20% 1D, market cap $62.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QTEX ranks #570 in composite RQD confidence.
How does QTEX compare to SKIN and LNSR in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, SKIN (SkinHealth Systems Inc. (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -26.9%, cap $67.5M) and LNSR (LENSAR Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $69.7M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for QTEX?
Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue (-99.1% YoY), -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is QTEX trading relative to its 50-day, 200-day, and 52-week technical levels?
QTEX last traded at $1.12 (-8.20% on volume of 2,729,255 shares), positioning the stock +1.82% above its 50-day simple moving average ($1.10) and +15.46% above its 200-day simple moving average ($0.97). Across its 52-week range of $0.28 to $3.85, QTEX sits at the 23.5% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.26).
QTEX — QTREX Quantum Ltd.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
QTREX Quantum Ltd. (QTEX) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.12 (-8.20% 1D, market capitalization $62.7M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 0.7%, operating margin of -60.0%, and free cash flow yield of -13.49%.
- Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
QTREX Quantum Ltd. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile does not describe its products, customers, or revenue model. Reported revenue is $0.3M for FY 2025 and — for both FY 2024 and FY 2023, indicating minimal commercial revenue against operating losses.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), QTREX Quantum Ltd. (QTEX) reported $289.0K in annual revenue (up from $31.5M in FY2024, -99.1% YoY) and -$13.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($34.0M revenue, -$11.3M net income) through FY2025, QTEX scaled operating cash flow to -$9.9M and free cash flow to -$10.0M, backed by $5.3M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -13.49% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.28 – $3.85 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector context provided is the Health Care / Medical/Dental Instruments classification. A prospective investor should watch whether the quantum test results referenced in the news flow translate into any commercial revenue, since current revenue of $0.3M provides little operating base to absorb further losses.
- Key Question #1: Can QTEX sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $289.0K and free cash flow of -$10.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is QTEX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
QTEX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for QTREX Quantum Ltd. (QTEX) • Click "Debate This Headline" to argue it in the Roar Pit below
Moomoo report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Globes - Israel Business News report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.
QTEX Bull vs. Bear Conversation Board — What's Your Call at $1.12?
Shares surged after hours on quantum test results and the company regained Nasdaq bid-price compliance, preserving capital-market acces
Long QTEX at $1.22 targeting $1.54. Shares surged after hours on quantum test results and the company regained Nasdaq bid-price compliance, preserving capital-market access.. Institutional whale score is 10/20 and the risk/reward vs. the $0.28 52-week low is skewed heavily in favor of bulls.
@TapeReader_Pro Agree on the RQD 36/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.22 and keeping dry powder in case we test $1.13.
Negative FCF of -$10.0M against $0.3M revenue, a Piotroski F-Score of 2/9, and ROIC of -35% signal sustained cash burn and weak forensi
Fading this rally in QTEX at $1.22. Negative FCF of -$10.0M against $0.3M revenue, a Piotroski F-Score of 2/9, and ROIC of -35% signal sustained cash burn and weak forensic health.. With a beta of 1.0 and the stock sitting at $1.22 (52-wk range $0.28–$3.85), the easy multiple expansion is already priced in.